29 марта, 14:11

The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton

The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton

12 марта, 17:52

5 Growth Stocks in MedTech Set to Scale Higher in 2018

The U.S. MedTech markets have been riding high with merger and acquisitions in focus.

09 марта, 15:17

Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

22 февраля, 18:45

Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?

ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

30 января, 15:49

The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

29 января, 14:47

Sanofi покупает бельгийскую Ablynx за €3,9 млрд

Французская фармацевтическая компания Sanofi договорилась о покупке бельгийской биотехнологической компании Ablynx за €3,9 млрд ($4,8 млрд), сообщает Reuters.

29 января, 14:47

Sanofi покупает бельгийскую Ablynx за €3,9 млрд

Французская фармацевтическая компания Sanofi договорилась о покупке бельгийской биотехнологической компании Ablynx за €3,9 млрд ($4,8 млрд), сообщает Reuters.

26 января, 17:10

Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

23 января, 17:28

J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve

J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.

Выбор редакции
22 января, 18:19

Sanofi покупает биотехнологическую Bioverativ в США

Французский фармацевтический концерн Sanofi договорился о покупке биотехнологической компании Bioverativ (США) за $11,6 млрд.

Выбор редакции
22 января, 18:19

Sanofi покупает биотехнологическую Bioverativ в США

Французский фармацевтический концерн Sanofi договорился о покупке биотехнологической компании Bioverativ (США) за $11,6 млрд, сообщила Sanofi.

19 января, 18:13

Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?

J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.

18 января, 17:26

J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

18 января, 17:13

J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?

The positive trend seen in J&J's (JNJ) pharma segment sales in Q3 is likely to continue in Q4. Strong pharma performance and contribution from acquisitions should support the top line.

29 декабря 2017, 22:43

4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

15 декабря 2017, 17:21

The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda

The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda

11 декабря 2017, 17:40

3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

06 декабря 2017, 17:21

Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?

Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.

21 ноября 2017, 18:08

United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

14 ноября 2017, 01:18

Biotech ETFs: What Lies Ahead?

It's been a good year for biotech ETFs, can the rally continue?